EPO and anemia: The difference in life expectancy for women with ESRD on hemodialysis as compared to those without the disease is attributed to the low doses of erythropoietin administered during dialysis, which increases their chances of developing anemia along with comorbidities such as low bone mineral densities that necessitate treatment with temporary vascular access [33].